Drug Profile
Catequentinib - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical
Alternative Names: AL-3818; ALTN; Anlotinib; Anlotinib hydrochloride; Anrotinib; FOCUS VLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
- Developer Advenchen Laboratories; Akeso Biopharma; Chia Tai Tianqing Pharmaceutical Group; Henan Cancer Hospital; Peking University People's Hospital; Tianquan Pharmaceutical
- Class Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorinated hydrocarbons; Indoles; Quinolines; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Liver cancer; Nasopharyngeal cancer; Soft tissue sarcoma; Synovial sarcoma; Thyroid cancer
- Phase II Bone cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Phase I/II Acral lentiginous melanoma; Endometrial cancer
- No development reported Solid tumours
Most Recent Events
- 18 Jan 2024 Efficacy and adverse events data from the phase II ALTER-G-001 trial in Gastrointestinal cancer presented at Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 20 Oct 2023 Efficacy and safety data from the phase II trial in cervical cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 Updated efficacy and safety data from the phase II neoALTALL trial in Triple-negative-breast-cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)